Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder in children: A case report and review of the literature

Pediatr Blood Cancer. 2022 Sep;69(9):e29862. doi: 10.1002/pbc.29862. Epub 2022 Jul 11.

Abstract

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD) is a rare benign lymphoproliferative disorder, recently redefined by the 2016 World Health Organization classification of lymphoid neoplasms. In adults, PCSM-TCLPD responds well to monotherapy with surgical excision or local radiation, with or without topical/injected corticosteroids; in contrast, PCSM-TCLPD has only rarely been reported in children, in whom treatments favored in adults may be non-optimal. We present a 14-year-old male with PCSM-TCLPD on the forehead, who achieved complete remission following biopsy, topical corticosteroids, and surgical excision. We also review all literature-reported cases of pediatric PCSM-TCLPD, emphasizing the disorder's benign nature and treatment responsiveness in children.

Keywords: PCSM-TCLPD; lymphoproliferative disorder; pediatric cutaneous oncology; pediatric oncology; peripheral T-cell lymphoproliferative disorder; primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

Publication types

  • Case Reports
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • CD4-Positive T-Lymphocytes / pathology
  • Child
  • Glucocorticoids
  • Humans
  • Lymphoma, T-Cell, Cutaneous* / therapy
  • Lymphoproliferative Disorders* / pathology
  • Male
  • Skin Neoplasms* / pathology

Substances

  • Glucocorticoids